[Treatment of chronic human Chagas disease with itraconazole and allopurinol. Preliminary report].
The aim of this work was to assess the efficacy of itraconazole and allopurinol in chronic Chagas disease. Two hundred two subjects (137 infected, 59 with Chagas cardiopathy and 6 with non chagasic cardiopathy) were randomly assigned to be treated with itraconazole (87 subjects receiving 6 mg/kg/day for 120 days), allopurinol (68 subjects receiving 8.5 mg/kg/day for 60 days) or placebo (47 subjects during 60 days). Medications were well tolerated. Indirect hemagglutination test was modified in 5 subjects (3.2%) after treatment. Initially positive xenodiagnosis became negative in 34 of 36 subjects (94.4%) treated with itraconazole and 8 of 10 subjects (80%) treated with allopurinol. Initially normal EKG was not modified in 100% of patients receiving placebo, 84.9% receiving itraconazole and 86.7% receiving allopurinol. Initially abnormal EKG became normal in 10 of 31 subjects (32%) receiving itraconazole, 8 of 20 (40%) receiving allopurinol and none of 8 receiving placebo. It is concluded that xenodiagnosis and EKG improvements indicate that itraconazole and allopurinol have a role in the treatment of chronic Chagas disease. A 36 months follow up of these patients will help to confirm this conclusion.
Apt
W
W
Unidad de Parasitología, Facultad de Medicina, Universidad de Chile, Santiago.
Aguilera
X
X
Arribada
A
A
Pérez
C
C
Miranda
C
C
Zulantay
I
I
Apt
P
P
Cortés
P
P
Rodríguez
J
J
D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use*; D014355:Chagas Disease / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002908:Chronic Disease; D004351:Drug Resistance; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors
D017964:Itraconazole; D000493:Allopurinol
Tratamiento de la enfermedad de Chagas humana crónica con itraconazol y alopurinol. Informe preliminar.